Investors & Media

Corporate News

• May 13, 2021Annovis Bio Files for FDA Orphan Drug Designation for ANVS401 for the Treatment of Alzheimer’s Disease in Persons with Down Syndrome
• May 11, 2021Annovis Bio to Participate at the Benzinga Global Small Cap Conference and Present to Investors on May 13, 2021
• May 10, 2021Annovis Bio to Ring Closing Bell at the New York Stock Exchange

Neurology News

• October 01, 2019Axonal Transport and Neurological Disease
• May 21, 2019How did the amyloid hypothesis go from promising to perilous in the search for Alzheimer’s treatments?
• April 30, 2019After amyloid failures, it’s time to take a new tack for treating Alzheimer’s

MORE NEUROLOGY NEWS